FindTrial
Sign In

Evidence based evaluation and mechanism study of Qi Gui Xue An Tang in the treatment of acquired bone marrow failure related bleeding

Evidence based evaluation and mechanism study of Qi Gui Xue An Tang in the treatment of acquired bone marrow failure related bleeding

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002592
Enrollment
Unknown
Registered
2025-12-30
Start date
2025-08-21
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acquired bone marrow failure disease

Interventions

Experimental group:Western medicine treatment+Qi Gui Xue An Tang
Control group:Western medicine treatment + placebo

Sponsors

The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Refer to the diagnostic criteria for blood disorders in "Internal Medicine of Traditional Chinese Medicine (4th Edition of the New Century)/National Higher Education Textbook of Traditional Chinese Medicine Industry for the 13th Five-Year Plan". (1) Meets the diagnostic criteria for acquired bone marrow failure disorders and is accompanied by bleeding (epistaxis, oral bleeding, hematuria, skin bleeding). (2) Meets the diagnostic criteria for hemorrhagic disorders in Traditional Chinese Medicine. (3) Based on the objectives of each phase of the clinical trial and the characteristics of the disease, determine the age range of subjects, generally 18–65 years old. (4) Sign the informed consent form.

Exclusion criteria

Exclusion criteria: (2) If the disease worsens during the course of illness. (4) Individuals under 18 years of age, pregnant or breastfeeding women, those with allergic constitutions, and those allergic to this medication. (5) Patients with severe primary diseases of the cardiovascular, cerebrovascular, liver, or kidney systems, or with psychiatric disorders.

Design outcomes

Primary

MeasureTime frame
Improvement rate of bleeding;—

Secondary

MeasureTime frame
Length of Stay;28-day bleeding-related mortality;Interval between platelet transfusions;Total Platelet Infusion Volume;Tongue appearance;Pulse condition;Traditional Chinese Medicine symptom bleeding score;White blood cell;Red blood cells;platelet;Percentage of reticulocytes;Peripheral blood T lymphocyte subsets;Cytokine Interleukin 6;Cytokine Interleukin10;Cytokine Interleukin 4;CytokineI nterferon-gamma;Routine bone marrow examination;—

Countries

China

Contacts

Public ContactShu Deng

Zhejiang Provincial Traditional Chinese Medicine Hospital

dengshu918@163.com13867132460

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026